These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Maternal serum screening for neural tube defects and Down syndrome. Keith D. Clin Lab Sci; 1992 May 02; 5(5):274-6. PubMed ID: 10150964 [No Abstract] [Full Text] [Related]
10. Maternal serum alpha-fetoprotein screening: report of a pilot project in Iowa. Williamson RA, Hanson JW, Grant SS. Iowa Med; 1986 Feb 02; 76(2):61-2, 63-4. PubMed ID: 2420743 [No Abstract] [Full Text] [Related]
11. [Defects in neural tube closure in the Vaud canton 1980-1992. The impact of prenatal diagnosis]. Marguerat P, Addor MC, Pescia G, Maillard-Brignon C, Laurini RN, Hohlfeld P, Vial Y, Weihs D. Rev Med Suisse Romande; 1994 Oct 02; 114(10):851-9. PubMed ID: 7526434 [No Abstract] [Full Text] [Related]
15. Screening for fetal neural tube defects: rationale and experience. Brock DJ. Prog Clin Biol Res; 1982 Oct 02; 103 Pt B():461-72. PubMed ID: 6187021 [No Abstract] [Full Text] [Related]
16. Screening model of studying alpha-foetoprotein of maternal serum (S-AFP) organized within central dispensary follow-up of pregnant women in Baranya region. Kóbor J, Pejtsik B, Pácsa S. Sante Publique (Bucur); 1982 Oct 02; 25(3):193-9. PubMed ID: 6187074 [No Abstract] [Full Text] [Related]
17. Neural tube defects in New South Wales: management and preventive policies, 1965-1980. Field BR, Kerr CB. Med J Aust; 1982 Oct 02; 2(12-13):667-70. PubMed ID: 6174849 [Abstract] [Full Text] [Related]
18. The South Wales NTD screening experience. Bobrow M. Lancet; 1983 Jul 23; 2(8343):222-3. PubMed ID: 6191166 [No Abstract] [Full Text] [Related]